BioLife Solutions, Inc.
NASDAQ:BLFSMedical - Instruments & Supplies
+$0.40 today
- Market cap
- $1.89B
- Beta
- 1.97
- P/E (TTM)
- -119.9
- EPS (TTM)
- -$0.22
Volume 4.39M
Average 0.52M
BLFS Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
BioLife Solutions, Inc.NASDAQ: BLFS
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow declines year over year
Q1 FY2026 investing cash flow of $1.83M (cash outflow) fell 93.3% year over year, ahead of the -247.4% change in trailing-twelve-month investing cash flow. Over 3 fiscal years it compounded at +7.2% a year.
Context
- Investing cash flow amounted to 74.4% of revenue in FY2025, up 3.5 pp from a year earlier.
- Investing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -93.3% holds above the trailing-twelve-month pace of -247.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (71.54M) USD
- Year-over-year change
- -222.7%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (71.54M) | -222.7% |
| FY2024 | 2024-12-31 | 58.3M | +226.8% |
| FY2023 | 2023-12-31 | 17.84M | +130.7% |
| FY2022 | 2022-12-31 | (58.12M) | -359.7% |
| FY2021 | 2021-12-31 | (12.64M) | — |
Investing Cash Flow vs competitors
How BLFS compares with its peers on the latest reported figures
- BLFS's LTM Mar 2026 investing cash flow of $46.19M is the 3rd largest of the 11 companies compared; the peer median is $18.14M.
- Its year-over-year change of -247.4% is the lowest of 11, against a peer median of +25.3%.
- Investing cash flow amounts to 46.3% of revenue for BLFS, versus a peer median of 7.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $451.5M | +214.9% | — | 66.9% | |
| LTM Apr 2026 | $149.69M | +474.9% | +83.5% | 30.2% | |
| LTM Mar 2026 | $46.19M | -247.4% | +7.2% | 46.3% | |
| LTM Jan 2026 | $38.33M | +94.5% | — | 45.8% | |
| LTM Aug 2026 | $35.42M | -210.0% | -29.5% | 4.0% | |
| LTM Sep 2026 | $33.8M | -62.6% | — | 5.4% | |
| LTM Mar 2026 | $23.45M | -29.5% | +46.3% | 8.7% | |
| LTM Apr 2026 | $13.14M | +132.8% | — | 4.5% | |
| LTM Jun 2026 | $12.83M | -34.7% | — | 2.3% | |
| LTM Sep 2026 | $9.95M | +38.6% | -41.3% | 3.8% | |
| LTM Jun 2026 | $290K | +12.0% | -5.8% | 24.5% | |
| Peer median (excluding BLFS) | $18.14M | +25.3% | -5.8% | 7.1% | |
Competitors are the stored peer set for BLFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.64M) | (139.81M) | (66.43M) | (20.18M) | (4.6M) |
| Depreciation & Amortization | 12.87M | 16.47M | 12.3M | 5.49M | 4.69M |
| Deferred Income Tax | (20.13M) | (5.24M) | (62K) | (64K) | 65K |
| Stock-Based Compensation | 13.96M | 25.33M | 31.67M | 30.92M | 22.99M |
| Change in Working Capital | (2.26M) | (14.91M) | 1.47M | 227K | (8.91M) |
| Accounts Receivables | (10.13M) | (10.75M) | 15.35M | (2.9M) | 264K |
| Inventory | 114K | (6.56M) | (8.55M) | 781K | (1.27M) |
| Accounts Payables | 2.02M | 414K | (8.43M) | 26K | (2.09M) |
| Other Working Capital | 5.74M | 1.99M | 3.09M | 2.32M | (5.82M) |
| Other Non-Cash Items | (1.64M) | 109.65M | 8.56M | (7.96M) | 5.87M |
| Operating Cash Flow | (4.84M) | (8.49M) | (12.5M) | 8.43M | 20.12M |
| Capital Expenditures | (8.39M) | (10.39M) | (6.38M) | (3.23M) | (9.48M) |
| Acquisitions (Net) | 1.56M | 0 | 0 | 60.39M | 23.52M |
| Purchases of Investments | (6.37M) | (53.12M) | (27.1M) | (18.42M) | (127.17M) |
| Sales of Investments | 6.37M | 8.92M | 56.17M | 21.92M | 41.59M |
| Other Investing Activities | (5.82M) | (3.54M) | (4.86M) | (2.37M) | 0 |
| Investing Cash Flow | (12.64M) | (58.12M) | 17.84M | 58.3M | (71.54M) |
| Debt Repayment | (2.89M) | 17.84M | (498K) | (6.61M) | (10M) |
| Common Stock Issued | 1.27M | 192K | 10.24M | 202K | 18K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.16M) | (1.71M) | 845K | (377K) | (942K) |
| Financing Cash Flow | (2.78M) | 16.32M | 10.59M | (6.78M) | (10.92M) |
| Effect of Forex Changes | (282K) | (108K) | 35K | 0 | 0 |
| Net Change in Cash | (20.59M) | (50.4M) | 15.97M | 59.95M | (62.35M) |
| Free Cash Flow | (13.22M) | (18.87M) | (18.88M) | 5.2M | 10.64M |
BioLife Solutions, Inc.
NASDAQ:BLFS
Intrinsic Alpha fair value
Locked
Current Price
$38.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.